US2020032218A1PendingUtilityA1

Virus strains

72
Assignee: BIOVEX LTDPriority: Jan 21, 2000Filed: Apr 2, 2019Published: Jan 30, 2020
Est. expiryJan 21, 2020(expired)· nominal 20-yr term from priority
Inventors:Robert Coffin
A61P 43/00A61P 37/04A61P 35/04A61P 31/00A61P 35/00A61P 25/00A61P 25/28A61P 25/02A61K 35/763C12N 7/00A61K 48/00C12N 2710/16643C12N 15/869A61K 2039/55522A61K 2039/55516C12N 2710/16021C12N 2710/16632C12N 2710/16033C12N 15/86
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.

Claims

exact text as granted — not AI-modified
1 . Use of a modified, oncolytic, non-laboratory virus strain in the manufacture of a medicament for the oncolytic treatment of cancer. 
     
     
         2 - 61 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.